Activity and specificity of KRAS variants-directed Revolution Medicines Company (RMC) compounds for pleural effusion-derived non-small cell lung cancer cell lines. (PubMed, Transl Lung Cancer Res) - Oct 15, 2026 - "The clinical therapy for KRAS G12C mutated lung cancers has been revolutionized by the approval of the covalent inhibitors Sotorasib and Adagrasib...A series of Revolution Medicines Company (RMC) compounds were developed, targeting all KRAS variants and KRAS wildtype, namely (RMC-6236, daraxonrasib), KRAS G12C (RMC-6291, elironrasib), KRAS G12D (RMC-9805, zoldonrasib) and KRAS G12V (RMC-5217) with more agents under development...Increased resistance to RMC-6236 has been associated with elevated expression or likely monoubiquitylation of KRAS. The limited activity of the RMC KRAS(ON) compounds may be supplemented by conventional KRAS(OFF) compounds or other glues or degraders."
Journal • Pleural effusion • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • KRAS
|
|
Gerhard Hamilton; Karl Kashofer; Lukas Weigl; Marie-Therese Eggerstorfer; Martin Hohenegger; Maximilian J Hochmair; Maximilian Rieche; Sandra Stickler
|